Steven E. Benner, MD, Senior Vice President and Global Therapeutic Head for Oncology at Astellas Oncology discusses the use of enzalutamide for men with metastatic castration-resistant prostate cancer. This abstract was presented by Gerhardt Attard, MD, PhD of The Institute of Cancer Research at the 2017 ASCO Annual Meeting in Chicago, IL.
Abstract 5004: A Phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
Advertisement